Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Core Viewpoint - Incyte has received approval from the European Commission for Zynyz (retifanlimab) as a first-line treatment for advanced squamous cell carcinoma of the anal canal (SCAC) [1] Group 1 - The approval marks a significant milestone for Incyte in expanding its oncology portfolio [1] - Zynyz is indicated for patients with advanced SCAC, which is a challenging condition with limited treatment options [1] - This approval is expected to enhance Incyte's market presence in the European oncology sector [1]